MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
$53,615K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income
Accrued royalties
Depreciation and amortization
Others
Negative Cash Flow Breakdown
Accounts receivable, net
Prepaid expenses and other asset...
Deferred taxes
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income
24,711
29,492
27,490
26,617
Stock-based compensation
11,406
10,191
9,768
9,691
Deferred taxes
-4,938
2,515
2,356
18,800
Depreciation and amortization
19,640
20,919
22,613
68,804
Unrealized (gain) loss on investment in equity securities
741
5,753
273
3,140
Non-cash operating lease expense
456
453
555
358
Non-cash interest
357
358
351
340
Contingent consideration fair value adjustment
-622
-182
-5,727
-14,470
Loss (gain) on disposal of assets
-
-
-87
-295
Loss on extinguishment of debt
-
-
0
0
Amortization of inventory step up
-
-
0
0
Asset impairment charges
-
-
0
767
Accounts receivable, net
19,077
-25,528
27,856
26,965
Inventories
-305
437
-3,732
8,160
Prepaid expenses and other assets
10,334
-2,687
4,460
6,454
Accounts payable
-1,116
5,358
-7,235
13,766
Accrued royalties
21,622
-14,655
-2,750
15,217
Income taxes
-1,770
14,087
472
-12,548
Accrued government rebates
2,975
-4,737
6,123
4,166
Returned goods reserve
960
-6,451
-502
1,322
Accrued expenses, accrued compensation, and other
12,835
-20,998
5,623
1,821
Net cash and cash equivalents provided by operating activities
56,669
58,375
30,367
44,055
Acquisition of alimera, net of cash acquired
-
-
-
0
Acquisition of alimera, net of cash acquired-Alimera
-
-
0
-
Acquisition of product rights, intangible assets, and other related assets
0
5,250
159
60
Acquisition of property and equipment, net
3,054
6,074
1,244
6,103
Proceeds from the sale of building
-
-
0
0
Net cash and cash equivalents used in investing activities
-3,054
-11,324
-1,403
-6,163
Proceeds from convertible notes
-
-
0
0
Proceeds from term loan
-
-
0
0
Purchase of capped call transaction
-
-
0
0
Principal payments on borrowings
4,062
4,063
10,156
0
Debt issuance costs
-
-
0
0
Repayment on borrowings under credit agreement
-
-
-6,093
2,031
Payment of accrued licensor payment
-
-
0
0
Series a convertible preferred stock dividends paid
0
0
0
344
Proceeds from stock option exercises and espp purchases
308
2,202
38
9,790
Proceeds from public offering
-
-
0
-
Treasury stock purchases for restricted stock vests
813
19,755
611
1,044
Payment of novitium contingent consideration
80
-
0
26
Net cash and cash equivalents used in financing activities
-4,647
-21,616
-4,636
6,345
Effect of exchange rate changes on cash, cash equivalents and restricted cash
67
156
-1,353
576
Net change in cash, cash equivalents, and restricted cash
49,035
25,591
22,975
44,813
Cash, cash equivalents, and restricted cash, beginning of period
311,212
285,621
262,646
144,894
Cash, cash equivalents, and restricted cash end of period
360,247
311,212
285,621
262,646
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$24,711K
(1.99%↑ Y/Y)
Accrued royalties
$21,622K
(61.31%↑ Y/Y)
Depreciation and
amortization
$19,640K
(-57.46%↓ Y/Y)
Accrued expenses,
accrued compensation,...
$12,835K
(345.98%↑ Y/Y)
Stock-based compensation
$11,406K
(-38.25%↓ Y/Y)
Accrued government
rebates
$2,975K
(-78.98%↓ Y/Y)
Returned goods reserve
$960K
(-89.80%↓ Y/Y)
Non-cash operating lease
expense
$456K
(-46.10%↓ Y/Y)
Non-cash interest
$357K
(-46.32%↓ Y/Y)
Inventories
-$305K
(-119.90%↓ Y/Y)
Net cash and cash
equivalents provided by...
$56,669K
(-48.86%↓ Y/Y)
Effect of exchange rate
changes on cash, cash...
$67K
(-87.68%↓ Y/Y)
Canceled cashflow
$38,598K
Net change in cash,
cash equivalents,...
$49,035K
(-32.77%↓ Y/Y)
Canceled cashflow
$7,701K
Accounts receivable, net
$19,077K
(414.34%↑ Y/Y)
Prepaid expenses and
other assets
$10,334K
(275.45%↑ Y/Y)
Deferred taxes
-$4,938K
(28.63%↑ Y/Y)
Income taxes
-$1,770K
(48.77%↑ Y/Y)
Accounts payable
-$1,116K
(-112.94%↓ Y/Y)
Unrealized (gain) loss on
investment in equity...
$741K
(225.81%↑ Y/Y)
Contingent consideration
fair value...
-$622K
(94.25%↑ Y/Y)
Proceeds from stock
option exercises and...
$308K
(-91.84%↓ Y/Y)
Net cash and cash
equivalents used in...
-$4,647K
(60.12%↑ Y/Y)
Net cash and cash
equivalents used in...
-$3,054K
(88.59%↑ Y/Y)
Canceled cashflow
$308K
Principal payments on
borrowings
$4,062K
(0.00%↑ Y/Y)
Treasury stock purchases
for restricted...
$813K
(-92.30%↓ Y/Y)
Acquisition of property and
equipment, net
$3,054K
(-52.93%↓ Y/Y)
Payment of novitium
contingent consideration
$80K
Buy us a coffee
ANI PHARMACEUTICALS INC (ANIP)
ANI PHARMACEUTICALS INC (ANIP)